GZ
Insider
Greg Zante
Chief Financial OfficerGreg Zante (Chief Financial Officer) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales), most often in Viking Therapeutics, Inc. (VKTX). The largest single filing was $1.8M of VKTX (56,161 sh across 3 lots, as filed), executed Jan 5.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
3
0 buys · 3 sells
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$2.8M
shares × price, as filed
Last traded
Jul 29
Filed Jul 29
Median ADV $77.4M across their filed names
Open performance→Volume by month
Buys $0
Sells $15.0M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
VKTXRecent filings
VKTXSALE
Viking Therapeutics, Inc.
View filing →
$710K21,217 sh × $33.47
Exec Jul 29
Filed Jul 29 · 8:06 PM ET VKTXSALE Viking Therapeutics, Inc. View filing → $1.8M
56,161 sh across 3 lots
Exec Jan 5
Filed Jan 5 · 5:30 PM ET VKTXSALE Viking Therapeutics, Inc. View filing → $216K
6,185 sh × $35.00
Exec Oct 28 2025
Filed Oct 28 2025 · 5:30 PM ET VKTXSALE Viking Therapeutics, Inc. View filing → $118K
4,266 sh × $27.76
Exec Jul 3 2025
Filed Jul 3 2025 · 5:30 PM ET VKTXSALE Viking Therapeutics, Inc. View filing → $2.2M
50,309 sh across 2 lots
Exec Jan 6 2025
Filed Jan 6 2025 · 5:30 PM ET VKTXSALE Viking Therapeutics, Inc. View filing → $10.0M
130,481 sh across 7 lots
Exec Oct 28 2024
Filed Oct 28 2024 · 5:30 PM ET